Randomized Clinical Trial of Surgical vs. Percutaneous vs. Hybrid Revascularization in Multivessel Coronary Artery Disease: Residual Myocardial Ischemia and Clinical Outcomes at One Year—Hybrid coronary REvascularization Versus Stenting or Surgery (HREVS)
Table 3
Inclusion and exclusion criteria of the HREVS trial.
Inclusion criteria
Exclusion criteria
1. Male or female ≥18 years of age 2. II–IV Canadian Cardiovascular Society functional class of angina 3. Angiographically confirmed multivessel coronary artery diseases involving LAD, with lesions severity ≥70% diameter stenosis (DS) by quantitative coronary angiography (QCA), or 50–70% DS with functional evidence of ischemia by either FFR ≤0.80 or stress SPECT 4. At least 1 month after acute MI (in patients with history of MI) 5. Heart team-determined indication to coronary revascularization with equal feasibility to perform complete revascularization using either of the three methods (HCR, MVD-PCI, CABG) 6. Written informed consent for participation in the study, including random treatment allocation and compliance with study requirements inclusive of follow-up visits and 12 ± 1 month SPECT followed by control angiography
1. Acute coronary syndrome (ACS) 2. Any previous coronary revascularization (CABG, HCR, or PCI) 3. Presence of any condition or abnormality that in the opinion of the investigator would compromise the safety of the patient or the quality of the data 4. Pregnancy 5. Stenosis of the left main coronary artery requiring revascularization 6. Significant calcification or occlusion of a major coronary vessel 7. Left ventricle aneurysm or valvular heart disease requiring surgical management 8. Comorbidity associated with an increased procedural risk for any of the treatment strategies or other study procedures 9. Peripheral arterial disease with pain-free walking distance ≤50m 10. Life expectancy ≤5 years 11. Inability to comply with dual antiplatelet therapy (DAPT) 12. Inability to undergo follow-up procedures including long-term follow-up 13. Participation in another clinical study